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ABSTRACT
Expression based prediction of new genomic alterations in glioblastoma identified 
the de-ubiquitinase Ubiquitin Specific Peptidase 15 (USP15) as potential tumor 
suppressor gene associated with genomic deletions (11%). Ectopic expression of 
USP15 in glioblastoma cell-lines reduced colony formation and growth in soft agar, 
while overexpression of its functional mutant had the opposite effect. Evaluation of 
the protein binding network of USP15 by Mass Spectrometry in glioblastoma cells 
uncovered eight novel interacting proteins, including HECT Domain Containing E3 
Ubiquitin Protein Ligase 1 (HECTD1), whose mouse homologue has been associated 
with an inhibitory effect on the WNT-pathway. USP15 de-ubiquitinated and thereby 
stabilized HECTD1 in glioblastoma cells, while depletion of USP15 led to decreased 
HECTD1 protein levels. Expression of USP15 in glioblastoma cells attenuated WNT-
pathway activity, while expression of the functional mutant enhanced the activity. 
Modulation of HECTD1 expression pheno-copied the effects observed for USP15. In 
accordance, human glioblastoma display a weak but significant negative correlation 
between USP15 and AXIN2 expression. Taken together, the data provide evidence that 
USP15 attenuates the canonical WNT pathway mediated by stabilization of HECTD1, 
supporting a tumor suppressing role of USP15 in a subset of glioblastoma.
INTRODUCTION
Glioblastoma (GBM) is the most malignant 
primary brain tumor in adults with a dismal prognosis 
of only 15 to 18 months [1]. The tumor is refractory to 
most therapies, likely due to a plethora of genetic and 
epigenetic alterations affecting multiple cancer relevant 
pathways conferring enhanced adaptive plasticity to 
tumor cells [2, 3]. Interestingly, so far no strong addiction 
to single oncogene activation has been identified that 
was successfully druggable in patients. In a screen of a 
cohort of GBM for aberrantly expressed genes to infer 
underlying molecular alterations, we identified Ubiquitin 
Specific Peptidase 15 (USP15) (12q14.1) to be associated 
with genomic deletions, suggestive of a potential tumor 
suppressing function in GBM [4]. The region 12q14-15, 
comprising the USP15 locus, has been identified as a 
breakpoint rich region (BER) affecting a subset of GBM. 
BER results in complex patterns of gene alterations, 
including deletions, amplifications, rearrangements, 
and fusions that have been associated with worse 
outcome [5]. This chromosomal region is flanked by the 
proto-oncogenes CDK4 and MDM2 that are amplified 
individually or together in a subset of GBM, and co-
amplification overlaps significantly with BER.
USP15 belongs to the ubiquitin-specific protease 
(USP) family, which is the largest sub-group of de-
ubiquitinase enzymes (DUBs), and exerts cysteine 
endopeptidase activity [6]. Deregulation in the 
ubiquitination machinery has been associated with 
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several types of cancer and may serve as target for cancer 
therapy [7]. The function of USP15 has been mainly 
associated with the COP9 signalosome (CSN). CSN is 
a conserved multiprotein complex typically consisting 
of eight subunits designated as CSN1-CSN8 [8]. USP15 
is emerging as a multifunctional DUB regulating also 
multiple proteins involved in cancer relevant pathways 
thereby mediating both, tumor suppressing and oncogenic 
functions in a context dependent manner. Oncogenic 
properties have been reported from ovarian cancer, where 
USP15 stabilizes HPV16E6 [9], or from divers cancer cell 
lines where USP15 stabilizes the oncogene REST [10] or 
MDM2 [11], respectively. Further, an oncogenic role has 
been reported through interaction and stabilization of the 
TGF-β receptor I, potentially activating TGF-β signaling 
in a small subgroup (2%) of GBM [12]. On the other 
hand reports on tumor suppressing functions comprise the 
stabilization of p53 with subsequent induction of p21 [13], 
inhibition of EB1 by interacting and stabilizing the E3 
ligase that ubiquitinates EB1 [14], stabilization of APC, 
thereby attenuating the WNT signalling pathway [15], or 
stabilization of procaspase, promoting caspase 3 mediated 
apoptosis. Furthermore, the USP15 gene has been shown 
to be deleted in 25.37% of pancreatic cancer [16].
Here we investigated the function of USP15 in GBM 
by identifying its interaction partners, and determining 
their function in GBM cells.
RESULTS
Evaluation of gene copy number aberrations of 
USP15 in GBM revealed a deletion frequency of 10.9% 
(95% exact confidence interval [CI] 4.5-21.2) for our 
GBM dataset (NCH-EORTC, n= 64, human methylation 
450K BeadChip) which was corroborated in the GBM 
dataset of The Cancer Genome Atlas (TCGA) with a 
deletion frequency of 10.8% (95% [CI] 8.0-14.2) and 
an amplification frequency of 1.2% (95% CI, 0.4-2.8) 
(n=415, ACGH-244k) [2].
USP15 overexpression inhibits cell proliferation 
and growth in soft agar
In order to evaluate the effect of USP15 in human 
GBM, we stably transfected the GBM cell lines LN-229 
and LN-428 to ectopically express USP15 or its catalytic 
mutant USP15C298S, using a pIRES2-EGFP backbone with 
a V5 tag. Cysteine 298 is in the catalytic site (catalytic 
triad) of the protein, and mutation into serine abrogates the 
ability to de-ubiquinate proteins [17]. The selected clones 
were subjected to a proliferation assay over 5 days under 
standard conditions. Cell growth of USP15 overexpressing 
clones and clones expressing the mutant, USP15C298S, or 
corresponding EGFP-vector controls was significantly 
different (t-test, p-value < 0.01) in both GBM cell lines. 
The USP15 overexpressing clones grew less than the other 
clones (Figure 1). Furthermore, adhesion-independent cell 
growth as tested in the soft agar assay showed even more 
striking results. After 3 weeks of culture in soft agar the 
USP15 overexpressing cells displayed a reduced ability to 
form colonies as compared to the USP15C298S clones and 
the EGFP-vector controls in both cell lines (Figure 1). The 
LN-229 derived USP15 expressing clones even completely 
lost the ability to grow in soft agar. Interestingly, the 
clones expressing the mutant USP15C298S formed more and 
bigger colonies in soft agar than the EGFP-vector controls 
(Figure 1). This observation may suggest that the USP15 
mutant USP15C298S out-competes the endogenous USP15 
leading to enhanced cell proliferation in LN-229 and LN-
428 in vitro.
USP15 protein binding network in LN-229 GBM 
cells
In order to identify GBM-relevant molecular 
pathways in which USP15 is implicated, we aimed at 
identifying its protein binding partners in the GBM cell 
line LN-229. Immunoprecipitation (IP) of endogenous 
USP15 in LN-229 was followed by mass spectrometry 
(MS). In the control experiment an antibody against 
rabbit IgG was used. Fractions of the immunoprecipitated 
proteins were analyzed by Western blot and by SDS-
PAGE (silver staining) to confirm that the endogenous 
USP15 was expressed at a sufficient level for detection by 
MS. MS identified 502 proteins. From the top 11 proteins 
with 7 or more spectra and none in the IgG control, 8 
were confirmed in an independent IP/MS experiment 
(Table 1). From these top proteins three were known 
interactors of USP15: Squamous Cell Carcinoma Antigen 
Recognized By T Cells 3 (SART3) [18, 19, 20], USP11 
[21, 22] and USP4 [22], suggesting that IP-MS analysis 
worked efficiently. We selected four of the novel potential 
USP15 binding partners HECT Domain Containing E3 
Ubiquitin Protein Ligase 1 (HECTD1), Oxysterol Binding 
Protein-Like 3 (OSBPL3), and Kinesin Family Member 15 
(KIF15), Regulator Of Microtubule Dynamics 3 (RMDN3) 
that seem to be implicated in cancer relevant molecular 
mechanisms [23–30]. The interactions were validated 
by Western using the respective specific antibodies after 
loading proteins immunoprecipitated from LN-229 protein 
extracts with the AB against the endogenous USP15, or 
the control AB against rabbit IgG, respectively (Figure 2, 
Supplementary Figure 1).
Interaction of USP15 with HECTD1
We then selected HECTD1 for further analyses. 
HECTD1 had the most spectra of the new binding partners 
in both experiments (Table 1). Furthermore, a recent report 
indicated that the murine homologue, Hectd1 is a negative 
regulator of the Wnt pathway [31]. Hectd1 was shown to 
tag Adenomatous polyposis coli (APC) with a Lys-63 
linked ubiquitin chain in HEK293 cells, thereby promoting 
APC-Axin interaction, leading to negative regulation 
Oncotarget110492www.impactjournals.com/oncotarget
of Wnt signaling. This Lys-63 ubiquitinilation of APC 
by Hectd1 is reversible by the de-ubiquitinase Trabid, 
resulting in Wnt pathway activation. Additionally, it was 
shown that the Trabid-Hectd1-APC complex interacts with 
proteins composing the striatin-interacting phosphatase 
and kinase (STRIPAK) complex that regulates cortical 
actin cytoskeleton dynamics [31]. Interestingly, our IP-MS 
analyses comprised proteins from the STRIPAK complex 
(Supplementary Table 1).
First we confirmed the interaction between USP15 
and HECTD1 in two additional GBM cell lines, LN-428 
and LN-18 after immunoprecipitation of the endogenous 
Figure 1: Effect of USP15 on cell growth in LN-229. (a) Structure of the wildtype USP15 construct with the V5 protein tag, and 
the respective catalytic mutant USP15C298S. (b) Protein expression by Western blot using an anti-V5 AB, loading control tubulin for the 
selected clones from LN-229 and LN-428 with stable expression of USP15, or USP15C298S (USPC/S), or empty vector controls. (c) Growth 
of USP15, or USP15C298S (USPC/S) overexpressing clones, and respective empty vector control (pIRES2/EGFP) followed over 5 days in 
culture. The error bars indicate standard deviations of triplicate samples. (d) Adhesion-independent growth in soft agar, representative 
images, and quantification of total colony numbers. Empty vector control, eV, black; USP15, blue; USP15C/S, green. Histogram shows 
data as mean +/-SD.
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USP15 by Western blot (Figure 2). Then we assessed the 
nature of the interaction between USP15 and HECTD1. 
Depletion of USP15 by siRNAs in LN-229 and LN-428 
resulted in a reduction of HECTD1 protein as determined 
by Western blot (Figure 3), suggesting a stabilizing effect 
of USP15 on HECTD1.
USP15 stabilizes E3 ligase HECTD1 via de-
ubiquitination
To better understand the USP15-HECTD1 
interaction we performed a de-ubiquitination assay. To 
this end, LN-229 cells ectopically expressing either 
USP15, the functional mutant USP15C298S, or the EGFP-
vector control, were transfected with a HA-Ubiquitin 
construct. Forty hours later cells were treated with 5μM 
of the proteasome inhibitor MG132 for 8 hours. Cells 
were lyzed and used for immunoprecipitation using 
an antibody against the endogenous HECTD1. The 
immunoprecipitated proteins were analyzed by Western 
blot using an anti-HA antibody. Western blot analysis 
revealed that overexpression of USP15 in LN-229 cells 
caused a reduction in HECTD1 ubiquitination, whereas 
USP15C298S increased HECTD1 ubiquitination (Figure 4). 
Again, suggesting that the mutant form out-competed the 
endogenous USP15. In accordance, the de-ubiquitination 
assay in LN-229 cells that were transfected with siUSP15, 
showed that knockdown of endogenous USP15 increased 
the incorporation of ubiquitin into HECTD1, as compared 
to the siRNA control cells (Figure 4). Taken together, 
these data suggest that USP15 is able to cleave the ub-
conjugates from HECTD1, thereby rescuing it from 
proteasome degradation, leading to stabilization of the 
protein. However, direct interaction remains to be shown.
HECTD1 overexpression in LN-229 cell lines 
inhibits growth in soft agar
Next, we aimed at elucidating the role of 
HECTD1 in GBM. We established LN-229 cells that 
stably express GFP-HECTD1 as confirmed by Western 
blot (Figure 5). We tested the effect of HECTD1 
on growth in soft agar. HECTD1 overexpressing 
clones displayed a strikingly reduced ability to form 
colonies as compared to the EGFP-vector control cells 
after 3 weeks (Figure 5). The empty vector carrying 
cells displayed 90-94% more colonies as compared 
to the HECTD1 overexpressing clones (Figure 5). 
Consistent with this finding, depletion of endogenous 
HECTD1 by siRNAs resulted in an acceleration of the cell 
Table 1: USP15 Interactors in glioblastoma cell lineLN-229
Identifier UniProt description
Number of spectra
1st IP 2nd IP
α-USP15 IgG control α-USP15 IgG control




recognized by T-cells 3
56 0 97 0
HECTD1 E3 ubiquitin-protein ligase HECTD1 25 0 68 0
OSBPL3 Oxysterol-binding protein-related protein 3 18 0 48 2
KIF15 Kinesin-like protein KIF15 17 0 41 0
DRP1 Dynamin-1-like protein 10 0 22 0
UBP11 Ubiquitin carboxyl-terminal hydrolase 11 14 0 24 0
UBP4 Ubiquitin carboxyl-terminal hydrolase 4 14 0 23 0
RMD3 Regulator of microtubule dynamics protein 3 11 0 11 0
GLNA Glutamine synthetase 9 0 19 0
CO4A Complement C4-A 7 0 10 0
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Figure 2: USP15 interacts with HECTD1 in GBM cell lines. Immunoprecipitation using an antibody against the endogenous 
USP15 in LN-229, LN-428, and LN-18 protein extracts, analyzed by Western blot using an antibody against HECTD1. The control 
immunoprecipitation was performed with anti-rabbit IgG.
Figure 3: USP15 knockdown leads to decreased HECTD1 protein levels. (a) USP15 knockdown with three siRNAs in LN-229 
and (b) two siRNAs in LN-428.
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Figure 4: USP15 de-ubiquitinates and stabilizes HECTD1 in LN-229. The de-ubiquitination assay was performed in cells 
transfected with an expression plasmid for HA-Ubiquitin that 40 hours after transfection were treated for 8 hours with the proteasome 
inhibitor MG132 (5μM). The cells were lyzed and used for IP using an antibody against the endogenous HECTD1, or an AB against rabbit 
IgG in the negative control. The immunoprecipitated proteins were then analyzed by Western blot using an anti HA antibody to detect 
ubiquitination. (a) LN-229 cells stably expressing USP15, the mutant USP15C/S, or the empty vector control, respectively. Lanes 1 to 3 
correspond to the input controls. The USP15 wt overexpressing LN-229 cells show lower ubiquitination levels of HECTD1 than the vector 
control. The mutant USP15-C/S overexpressing cells displayed the highest ubiquitination of HECTD1. (b) De-ubiquitination assay in LN-
229 depleted for endogenous USP15 by siRNA against USP15 or the respective si-control. LN-229 cells depleted for endogenous USP15 
display higher ubiquitination of HECTD1 than the sicontrol cells.
Figure 5: Effect of HECTD1 on cell growth. LN-229 clones stably overexpressing HECTD1 as determined by Western blot 
(respective RNA expression levels of HECTD1 [ectopic and endogenous] are shown in Figure 6c) (a) were tested for adhesion-independent 
growth in soft agar (b). Quantification of colonies revealed strong reduction of colony formation in HECTD1 overexpressing cells (c) (data 
as mean +/-SD).
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cycle as determined by fluorescence-activated cell sorting 
(FACS) (Supplementary Figure 2).
HECTD1 and USP15 have a negative effect on 
WNT pathway activity
Since the murine homologue of HECTD1 has 
been shown to interact with APC in HEK293 cells 
promoting the APC-Axin interaction and leading to 
negative regulation of Wnt signalling [31] we determined 
the effect of HECTD1 on the WNT pathway using the 
HECTD1 expressing LN-229 cell clones. The activation 
of the β-catenin dependent pathway was measured by 
the TCF/LEF reporter system (TOPflash/FOPflash 
luciferase assay). HECTD1 overexpressing LN-229 cells 
displayed reduced WNT pathway activity as compared to 
the respective EGFP-vector control cells (Figure 6). In 
accordance, differential qRT-PCR analysis revealed that 
HECTD1 overexpressing clones had significantly lower 
AXIN2 gene expression. AXIN2 is a direct canonical WNT-
pathway target gene, mediated through TCF/LEF factors, 
whose expression reflects canonical WNT-pathway 
activity [32, 33]. The decreased AXIN2 expression thus 
supports the notion that HECTD1 attenuated the WNT 
pathway (Figure 6). We then went back to test the effect 
of USP15 on WNT pathway activity by measuring 
AXIN2 expression as read-out in LN-229. The USP15 
overepxressing clones displayed significantly reduced 
Figure 6: HECTD1 downregulates WNT pathway activity in LN-229.  (a) WNT pathway activity was measured with the TCF 
luciferase reporter system (TOPflash/FOPflash) in LN-229 clones stably expressing HECTD1 and the empty vector control cells. The error 
bars indicate standard deviation of three independent experiments. AXIN2 (b) and HECTD1 (c) expression were measured by qRT-PCR 
relative to GAPDH. The histograms shown are representative of three independent experiments (data as mean +/-SD). The experiments are 
normalized to the empty vector control (eV).
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levels of AXIN2 expression as compared to the empty 
vector control, while the clones expressing the mutant 
USP15C298S exerted incereased expression (Figure 7a). We 
then confirmed the negative regulatory effect of USP15 on 
the WNT pathway in the LN-428 GBM cell line using the 
TCF/LEF WNT-pathway luciferase reporter. Compared 
to the EGFP-vector control, the USP15 overexpressing 
clones displayed a significantly attenuated WNT pathway 
activity, while the mutant USP15C298S overexpressing 
clones displayed a modest increase (Figure 7c).
Taken together, the data suggest that USP15 as well 
as HECTD1 are involved in the negative regulation of the 
WNT pathway in GBM.
USP15 and the Wnt pathway in human GBM
In order to evaluate whether the here delineated 
regulation of the WNT pathway through USP15 is of 
relevance in human GBM, we interrogated the relationship 
between expression of USP15 and the prototypic WNT 
target gene AXIN2 in human GBM samples using the 
TCGA dataset (n=107; normalized level 3 RNAseq data). 
A significant negative correlation was observed (Spearman 
correlation coefficient r=-0.24; Monte-Carlo test, p=0.01 
for 99 permutations) (Figure 8). Hence the data from GBM 
is compatible with the hypothesis that USP15 may exert a 
negative regulatory effect on the WNT pathway in GBM.
DISCUSSION
Our previous analyses of GBM datasets have 
pointed to the de-ubiquitinase USP15 as a candidate tumor 
suppressor gene for GBM based on gene expression and 
gene CNV patterns [4]. Functional evaluation of USP15 
by ectopic modulation of expression in GBM cell lines 
established an inhibitory effect on cell proliferation that 
was more remarkable under non-adherent conditions, 
while overexpression of the functional mutant enhanced 
cell growth under these conditions. USP15 is a 
multifunctional DUB whose context dependent function 
is mediated by the presence of cell specific substrates 
involved in multiple biologic mechanisms including 
cancer relevant pathways. Interestingly, these involve 
Figure 7: USP15 exerts an inhibitory effect on WNT pathway activity in GBM cell lines.  (a) Axin2 is canonical WNT-
pathway target gene and its expression was measured as read-out for WNT-pathway activity. qRT-PCR of Axin2 relative to GAPDH was 
peformed in LN-229 clones stably expressing USP15 (blue), the functional mutant USP15C/S (green), or the empty vector control cells 
(black). (b) Expression of USP15 relative to GAPDH. (c) Canonical WNT pathway activity was measured with the TCF/LEF luciferase 
reporter system (TOPflash/FOPflash) in LN-428 clones stably expressing USP15 (blue), USP15C/S (green), or the empty vector control. 
Histograms are representative of two independent experiments (data shown as mean +/-SD). In both cell lines overexpression of USP15 
attenuated WNT-pathway activity, while the functional mutant USP15C/S displayed an activating effect. The experiments are normalized 
to the empty vector control (eV).
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reportedly both tumor suppressing, but also oncogenic 
functions [9, 10, 11, 12, 13, 15, 34-37]. Exploration of the 
glioblastoma specific interactome of USP15 indentified 
HECTD1 as novel top binding partner. HECTD1 attracted 
our attention for its reported involvement in the negative 
regulation of the WNT pathway through ubiquitination 
of APC, promoting APC-Axin interaction [31]. We have 
demonstrated that downregulation of USP15 in GBM 
cells reduced HECTD1 levels, and that HECTD1 was 
substrate for de-ubiquinitation by USP15, but not by 
its functional mutant, suggesting that USP15 stabilizes 
HECTD1. We showed that HECTD1 negatively regulates 
canonical WNT activity in GBM cells similar to USP15, 
as determined by reporter assay or measuring expression 
of the prototypic WNT target gene AXIN2. Modulation of 
HECTD1 expression pheno-copied the effects of USP15 
in GBM cells. From these data we concluded that USP15 
may exert its negative regulatory effect on WNT pathway 
activity through stabilizing HECTD1.
The significant negative association of USP15 
expression with the canonical WNT pathway target 
gene AXIN2 in a human GBM dataset is consistant with 
a negative regulatory role of USP15 as proposed by our 
in vitro study. Hence, USP15 may indeed have a tumor 
suppressive role that is targeted in a subset of GBM by 
deletion (11%), resulting in enhanced WNT pathway 
activity. This adds a novel mechanism of WNT pathway 
deregulation observed in GBM that include genetic and 
epigenetic inactivation of negative regulators, such as 
Dickkopf, the family of Secreted Frizzled-Related Proteins 
(SFRPs), and the WNT inhibitory factor 1 (WIF1) that 
affect the canonical, and in the case of WIF1 also the 
non-canonical WNT pathway [4, 33, 38, 39]. This new 
mechanism of WNT pathway deregulation emphasizes the 
Figure 8: Association of USP15 expression and the WNT target gene AXIN2 in human GBM. Negative correlation between 
expression of USP15 and AXIN2 in the TCGA dataset (r=-0.24 spearman correlation; p=0.01, Monte-Carlo test, 99 permutations; n=107) 
for which RNAseq data is available. The solid pink line corresponds to the linear model (y= a +xb) and the purple line to the LOWESS 
smoother (locally-weighted polynomial regression [48]).
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importance of active WNT signalling for GBM biology. 
Ubiquitination and de-ubiquitination are interesting 
targets for drug development, especially in cancer [40]. 
Further study of the regulation of this USP15 interaction 
or the potential binding network of HECTD1 may allow 
development of new treatment strategies.
MATERIALS AND METHODS
Datasets, gene copy number analyses, RNAseq 
analyses
Gene copy number analyses was performed using 
human methylation 450K data from the NCH-EORTC 
glioblastoma dataset (n=64; GEO accession number 
GSE60274) [41] and ACGH-244k from TCGA (n=415) 
[42]. A mixture model using the R package CGHcall 
was used for classification as detailed previously [43]. 
The Spearman ‘rank’ correlation between two genes was 
calculated using level 3 RNAseq data from the TCGA 
GBM dataset (n=107) [42] and tested for significance 
using the Monte-Carlo test (99 permutations) [44]. The 
dbGaP accession number to the specific version of the 
TCGA data set is phs000178.v8.p7.
Glioblastoma cell lines
The GBM cell lines LN-229, LN-428, and LN-
18 have been established in our laboratory and were 
authenticated by DNA fingerprinting [45]. Cell lines 
were cultured in Dulbecco's modified Eagle's medium 
(Invitrogen, USA), supplemented with 5% fetal calf serum 
(Hyclone, USA) and 100 units/mL penicillin, 100 units/
mL streptomycin (Invitrogen, USA).
Plasmid construction and small interfering 
RNAs
The full-length pIRES2-EGFP-V5-USP15 was 
subcloned as follows: DNA fragments encompassing 
residues 1–1627 and 1628-3000 of the human USP15 
isoform 1 were amplified by platinum TaqDNA 
Polymerase High Fidelity (Invitrogen, USA) using a 
cDNA template derived from the LN-229 cell line using 
primers described in Supplementary Table 2. The first 
product was digested with Sal1 (Roche, Germany) and 
PST1 (NEB, USA), while the second was digested with 
Pst1 (NEB) and Xba1 (Invitrogen). The products were 
subjected to a triple T4 DNA ligation reaction (Promega, 
USA) overnight at 4°C together with the Stag-V5 pcDNA3 
vector that had been digested with Xho1 and Xba1. The 
Stag-V5 pcDNA3 vector carries the streptavidin (Stag) 
and V5 tag and was kindly provided by Prof. Widmann 
(University of Lausanne). Subsequently, the insert was 
subcloned into pBluescript SKII(+) (Stratagene) between 
the HindIII/Xba1 restriction sites, in order to add the 
polylinker. The full length V5-USP15 was cloned into 
the pIRESII-EGFP vector (Clontech, USA) between the 
HindIII/SacII restriction sites.
The catalytic mutant of USP15 (USP15C/S) was 
created by PCR mutagenesis using as a template the 
intermediate V5-USP15/pBluescript SKII construct and 
the primers described in Supplementary Table 2. After 
PCR, the product was subjected to Dpn1 digestion for the 
destruction of the initial plasmid template. The isolated 
mutated product was cloned into the pIRESII-EGFP vector 
between the HindIII/SacII restriction sites.
The pEGFP-HECTD1 construct was kindly provided 
by Cai Huang [46] and the HA-Ubiquitin by Dr. Phil Shaw 
(University Hospital Lausanne). The Wnt/β-catenin activity 
luciferase reporters TOP_FLASH and FOP_FLASH 
comprise T-cell factor (TCF)/β-catenin responsive elements 
that express synthetic firefly luciferase from a PGL4.10 
backbone with a minimal TATA box with 8 concatenated 
TCF binding sites, and 8 mutated binding sites, 
respectively (kindly provided by Prof. Tatiana Petrova, 
University of Lausanne) [47]. The pRL CMV Renilla 
luciferase (Promega AG) plasmid was used to normalize 
for transfection efficiency. All constructs were validated by 
sequencing (Microsynth, Switzerland). For transformation, 
bacteria (Ecoli strain DH5a9) were incubated with the 
plasmids for 30 minutes on ice, and subjected to heat shock 
for 45 s at 42°C. Bacteria were put on ice for 2minutes, 
and then left to recover in Luria Bertani (LB, Sigma, USA) 
liquid media without antibiotic for 45minutes at 37°C in a 
shaking incubator. Later bacteria were plated on petri dish 
with solid LB-agar (Fluka, USA) and the antibiotic for 
selection (ampicillin, kanamycin, Sigma).
Plasmid purification from liquid bacteria culture was 
performed with the Qiafilter Plasmid Midi kit (Qiagen, 
Netherlands), or the Qiaprep Spin Miniprep kit (Qiagen).
Cell transfection and establishment of stable cell 
lines
Cell lines were transfected with the system NEON 
electroporator (invitrogen) at 1400 Volts, 20 Width, and 
1 pulse using 100 μl tips. A ratio of 15μg of DNA/1*10^6 
cells was used, while the final concentration of transfected 
siRNA was 50 nM (sequences Supplementary Table 2). 
For stable transfections, cells were selected with G418 
(400-800 μg/mL). Resistant clones were selected, and 
isolated by cell sorting. Sorted cells were subjected to 
single clone culture and maintained under G418.
Crystal violet assay
Growth curves were performed in 12-well plates. 
In each well, 2-3 × 104 cells were seeded. At every time 
point, culture medium was removed, cells were washed 
with 1mL of 1X phosphate buffered saline (PBS), and 500 
μL of crystal violet solution was added per well. After 10 
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min, crystal violet solution was removed and plates were 
washed with 1× PBS. Plates were left to dry, and 500 μL 
of 1% sodium dodecyl sulfate (SDS) in distilled water was 
added per well. Absorbance was then measured at 595 nm 
using a plate reader.
Colony formation assay in soft agar
Soft agar assay was performed in 6-well plates in 
2mL of 1% agar in complete medium as the bottom layer, 
and 1 mL of 0.4% agar in complete medium as the top 
layer. 2 × 103 cells were seeded in triplicate. Cultures 
were maintained under standard conditions, and after 3 
weeks colonies were stained with 2-(4-iodophenyl)-3-
(4-nitrophenyl)-5-phenyl-2H-tetrazolium chloride (INT) 
(Sigma). The colonies were detected with an inverted 
phase-contrast microscope, where a group of 50 cells 
was scored as colony. Colonies were photographed and 
quantified by ImageJ program.
Immunoprecipitation and mass spectrometry
LN-229 cell lines were seeded in eight to ten 10cm 
cell culture plates and cultured until they reached 80% 
confluency. Cells were washed with 1x PBS and lyzed in 
500μl 1%NP40 lysis buffer (25mM Tris pH 7.5, 150mM 
NaCl, 1% NP40, 0.5mM, phenylmethylsulfonylfluoride 
(PMSF), protease inhibitor cocktail (Roche)). Lysates 
were centrifuged at 13000rpm for 10minutes. Protein 
concentration was measured using Bradford assay (Bio-
Rad Laboratories). For the first IP MS experiment 3 
mg of protein was used and for the second 5 mg. The 
concentration of the USP15 antibody (NB110-40690, 
Novus Biologicals, UK) and of the normal Rabbit IgG 
control (12-370, Millipore, Germany) was 5μg/mg of 
lysate. The mixture of antibody/lysate was left rotating 
gently at 4°C overnight. After 12 hours 100-120μl of 50% 
A agarose beads (Thermoscientific, USA) were added to 
the samples and were incubated while rotating at 4°C for 
four further hours. (Before use, the beads were washed 
with 1xPBS and centrifuged at 1000rpm for 1 min).
The mixture (beads-antibody-protein sample) was 
washed 5 times with 0.1%Tween-20/PBS. (Washing: 
500μl 0,1% Tween-20 PBS, mix, centrifuge for 2min at 
1000rpm/4°C). The 1/10 of pulldown product: 30μl of 2X 
SDS-loading buffers was added, boiled for 5 min at 95°C, 
5 μl of the sample were loaded onto a reducing SDS-
PAGE using standard methods, and the rest was loaded 
on another 10% gel in parallel for silver staining (Silver 
Staining Kit, SilverXpress, Invitrogen; according to the 
manifacturer’s instructions).
Western blot analysis
For Western blot analysis protein samples were 
loaded onto a reducing SDS-PAGE (acrylamide, 
Applichem, German;, 0.33M Tris pH 8.8, 0.1M SDS, 
0.1 ammonium persulfate, Biorad, USA;, TEMED, 
Biorad). The percentage of acrylamide was adjusted to 
the molecular size of the protein of interest: 8-10% for 
USP15, KIF15, RMDN3, and 6% for HECTD1. The 
samples were run for around 1h30 at 120V. Afterwards 
protein samples were transferred onto a nitrocellulose 
membrane (Amersham™Hybond™-ECL, USA). 
Transfer times were adjusted to the protein size: 1h30 at 
300mA at 4°C for USP15, KIF15, RMDN3, and 4hours 
at 300mA at 4°C for HECTD1. Protein markers used for 
the determination of the molecular weight: peqGOLD 
protein marker IV, V (Peqlab, Germany) and HiMark Pre-
stained HMW Protein standard (Invitrogen). After transfer, 
membranes were blocked in 5% milk (Rapilait) diluted 
in TBS-T for 1 hour in gentle rotation. Then membranes 
were incubated overnight at 4°C with the primary antibody 
(HECTD1, dilution 1:3000, NBP1-49926; KIF15, 1:3000, 
NBP1-49926; OSBPL3, 1:2000, NBP1-55151; RMDN3 
(FAM82A2) 1:5000, NBP1-47294 - all Novus Biologicals; 
anti-HA antibody, 1:5000, ThermoScientific; anti-v5 tag 
antibody, 1:2000, ab15828, abcam; USP15 monoclonal, 
1:2000, M01, clone1C10, Abnova; α-tubulin, 1:3000, 
T-6074, sigma). After 12hours, membranes were washed 
with 1xTBS-T three times and then re-incubated with the 
secondary antibody (ImmunoPure® Antibody, mouse, 
or rabbit IgG, Thermo scientific) at room temperature 
for 1hour, rewashed three times with 1xTBS-T. The 
blots were developed with Pierce ECL Western Blotting 
Substrate (Thermo scientific) and the signal was detected 
with Image Reader LAS-4000.
Statistical analysis
The Student t test was used to compare continuous 
variables between two groups. P values less than 0.05 
were considered statistically significant. Analyses were 
performed using (Prism 5, GraphPad, La Jolla, CA, USA). 
Results are marked with 1 asterisk (*) if p< 0.05 and 2 (**) 
if p< 0.01 and with 3(***) if p<0.001. All statistical tests 
were two-sided. Data are presented as mean values with 
standard deviation.
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